RxDoctor Payments Data

Scott Wiley, MD

Family Medicine · Cape Coral, FLNPI 1386625614

Payments from drug & device makers

$686in general payments, 2019–2025

Across 29 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$140
  • AbbVie$129
  • Astellas Pharma US Inc$108
  • Novo Nordisk$78
  • Pfizer$77
  • GSK$48
  • plus $108 from 5 others

What the payments were for

  • Food & beverage$686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen2$140
AbbVie6$129
Astellas Pharma US Inc2$108
Novo Nordisk4$78
Pfizer5$77
GSK4$48
Abbott2$39
Bayer1$21
Merck1$16
Dexcom, Inc.1$16
Johnson & Johnson1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$686 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$2,035
Medicare patients
35
Services billed
160

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin56$53,758
JanuviaSitagliptin Phosphate38$34,409
XareltoRivaroxaban28$24,742
EliquisApixaban18$17,920
Atorvastatin Calcium220$2,441
Rosuvastatin Calcium169$2,331
SynthroidLevothyroxine Sodium27$1,933
Levothyroxine Sodium158$1,826
Metoprolol Succinate74$1,743
Amlodipine Besylate196$1,685
Simvastatin124$1,517
Losartan Potassium135$1,494
Albuterol Sulfate HfaAlbuterol Sulfate38$1,286
Tamsulosin Hcl68$1,171
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,093

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$16$34,40938 claims
Johnson & JohnsonXarelto$15$24,74228 claims
PfizerEliquis$77$17,92018 claims
AbbVieSynthroid$129$1,93327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Cape Coral

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →